Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | BAY1436032: IDH1 inhibition in IDH1-mutated AML

Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, reports the Phase I safety and efficacy results of the mutant IDH1 inhibitor, BAY1436032 in subjects with IDH1-mutated acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).